INVESTOR ALERT: Investigation of Entrada Therapeutics, Inc. (TRDA) announced by Holzer & Holzer, LLC

Globe Newswire 18-May-2026 8:00 AM

ATLANTA, May 18, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Entrada Therapeutics, Inc. ("Entrada" or the "Company") (NASDAQ:TRDA) complied with federal securities laws. On May 7, 2026, Entrada announced ELEVATE-44-201 cohort 1 topline results in its Duchenne muscular dystrophy study. Cohort 1 of the study demonstrated an increase of 2.36% in dystrophin, which fell below analysts' expectations. The price of the Company's stock dropped following this news.

If you purchased Entrada stock and suffered?a?loss on that investment, you are encouraged to contact Corey D. Holzer, Esq. at cholzer@holzerlaw.com or Joshua Karr, Esq. at jkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com/case/entrada-therapeutics/ to discuss your legal rights.

Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2021, 2022, 2023, and 2025, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct.?More information about the firm is available through its website,?www.holzerlaw.com,?and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.? 

CONTACT:

Corey Holzer, Esq. 

(888) 508-6832 (toll-free)

cholzer@holzerlaw.com